| # | Title | Journal | Year | Citations |
|---|
| 1 | Basic Concepts in Population Modeling, Simulation, and Model‐Based Drug Development—Part 2: Introduction to Pharmacokinetic Modeling Methods | CPT: Pharmacometrics and Systems Pharmacology | 2013 | 542 |
| 2 | Modeling and Simulation Workbench for NONMEM: Tutorial on Pirana, PsN, and Xpose | CPT: Pharmacometrics and Systems Pharmacology | 2013 | 507 |
| 3 | Pharmacokinetics of Monoclonal Antibodies | CPT: Pharmacometrics and Systems Pharmacology | 2017 | 503 |
| 4 | Application of ggplot2 to Pharmacometric Graphics | CPT: Pharmacometrics and Systems Pharmacology | 2013 | 488 |
| 5 | Basic Concepts in Physiologically Based Pharmacokinetic Modeling in Drug Discovery and Development | CPT: Pharmacometrics and Systems Pharmacology | 2013 | 385 |
| 6 | Basic Concepts in Population Modeling, Simulation, and Model‐Based Drug Development | CPT: Pharmacometrics and Systems Pharmacology | 2012 | 336 |
| 7 | Sobol Sensitivity Analysis: A Tool to Guide the Development and Evaluation of Systems Pharmacology Models | CPT: Pharmacometrics and Systems Pharmacology | 2015 | 264 |
| 8 | Model Evaluation of Continuous Data Pharmacometric Models: Metrics and Graphics | CPT: Pharmacometrics and Systems Pharmacology | 2017 | 261 |
| 9 | Good Practices in Model‐Informed Drug Discovery and Development: Practice, Application, and Documentation | CPT: Pharmacometrics and Systems Pharmacology | 2016 | 248 |
| 10 | Applied Concepts in PBPK Modeling: How to Build a PBPK/PD Model | CPT: Pharmacometrics and Systems Pharmacology | 2016 | 232 |
| 11 | Application of Physiologically Based Pharmacokinetic (PBPK) Modeling to Support Dose Selection: Report of an FDA Public Workshop on PBPK | CPT: Pharmacometrics and Systems Pharmacology | 2015 | 218 |
| 12 | Model-Based Population Pharmacokinetic Analysis of Nivolumab in Patients With Solid Tumors | CPT: Pharmacometrics and Systems Pharmacology | 2017 | 195 |
| 13 | Basic Concepts in Population Modeling, Simulation, and Model‐Based Drug Development: Part 3—Introduction to Pharmacodynamic Modeling Methods | CPT: Pharmacometrics and Systems Pharmacology | 2014 | 189 |
| 14 | Timing of Antiviral Treatment Initiation is Critical to Reduce SARS‐CoV‐2 Viral Load | CPT: Pharmacometrics and Systems Pharmacology | 2020 | 170 |
| 15 | Establishing Best Practices and Guidance in Population Modeling: An Experience With an Internal Population Pharmacokinetic Analysis Guidance | CPT: Pharmacometrics and Systems Pharmacology | 2013 | 140 |
| 16 | A Review of Mixed‐Effects Models of Tumor Growth and Effects of Anticancer Drug Treatment Used in Population Analysis | CPT: Pharmacometrics and Systems Pharmacology | 2014 | 137 |
| 17 | Physiologically Based Pharmacokinetic Modeling and Simulation in Pediatric Drug Development | CPT: Pharmacometrics and Systems Pharmacology | 2014 | 127 |
| 18 | Model-Based Characterization of the Pharmacokinetics of Pembrolizumab: A Humanized Anti-PD-1 Monoclonal Antibody in Advanced Solid Tumors | CPT: Pharmacometrics and Systems Pharmacology | 2017 | 121 |
| 19 | Efficient Generation and Selection of Virtual Populations in Quantitative Systems Pharmacology Models | CPT: Pharmacometrics and Systems Pharmacology | 2016 | 118 |
| 20 | PBPK Models for CYP3A4 and P‐gp DDI Prediction: A Modeling Network of Rifampicin, Itraconazole, Clarithromycin, Midazolam, Alfentanil, and Digoxin | CPT: Pharmacometrics and Systems Pharmacology | 2018 | 109 |
| 21 | The impact of mathematical modeling on the understanding of diabetes and related complications | CPT: Pharmacometrics and Systems Pharmacology | 2013 | 106 |
| 22 | A Tutorial on Target-Mediated Drug Disposition (TMDD) Models | CPT: Pharmacometrics and Systems Pharmacology | 2015 | 101 |
| 23 | Application of Physiologically Based Pharmacokinetic Modeling to Predict Acetaminophen Metabolism and Pharmacokinetics in Children | CPT: Pharmacometrics and Systems Pharmacology | 2013 | 93 |
| 24 | A Review of Mathematical Models for Tumor Dynamics and Treatment Resistance Evolution of Solid Tumors | CPT: Pharmacometrics and Systems Pharmacology | 2019 | 90 |
| 25 | Translational Pharmacokinetic/Pharmacodynamic Modeling of Tumor Growth Inhibition Supports Dose-Range Selection of the Anti-PD-1 Antibody Pembrolizumab | CPT: Pharmacometrics and Systems Pharmacology | 2017 | 88 |
| 26 | Using Model-Based “Learn and Confirm” to Reveal the Pharmacokinetics-Pharmacodynamics Relationship of Pembrolizumab in the KEYNOTE-001 Trial | CPT: Pharmacometrics and Systems Pharmacology | 2017 | 85 |
| 27 | Model‐Informed Precision Dosing at the Bedside: Scientific Challenges and Opportunities | CPT: Pharmacometrics and Systems Pharmacology | 2018 | 84 |
| 28 | Consideration of a Credibility Assessment Framework in Model‐Informed Drug Development: Potential Application to Physiologically‐Based Pharmacokinetic Modeling and Simulation | CPT: Pharmacometrics and Systems Pharmacology | 2020 | 84 |
| 29 | Tisagenlecleucel Model‐Based Cellular Kinetic Analysis of Chimeric Antigen Receptor–T Cells | CPT: Pharmacometrics and Systems Pharmacology | 2019 | 83 |
| 30 | Predictive Performance of Physiologically Based Pharmacokinetic Models for the Effect of Food on Oral Drug Absorption: Current Status | CPT: Pharmacometrics and Systems Pharmacology | 2018 | 80 |
| 31 | A PBPK Model to Predict Disposition of CYP3A‐Metabolized Drugs in Pregnant Women: Verification and Discerning the Site of CYP3A Induction | CPT: Pharmacometrics and Systems Pharmacology | 2012 | 78 |
| 32 | Model‐Informed Drug Discovery and Development: Current Industry Good Practice and Regulatory Expectations and Future Perspectives | CPT: Pharmacometrics and Systems Pharmacology | 2019 | 75 |
| 33 | A Time to Event Tutorial for Pharmacometricians | CPT: Pharmacometrics and Systems Pharmacology | 2013 | 73 |
| 34 | Implementation of Quantitative and Systems Pharmacology in Large Pharma | CPT: Pharmacometrics and Systems Pharmacology | 2014 | 73 |
| 35 | NONMEM Tutorial Part I: Description of Commands and Options, With Simple Examples of Population Analysis | CPT: Pharmacometrics and Systems Pharmacology | 2019 | 72 |
| 36 | Population Pharmacokinetics of Obinutuzumab (GA101) in Chronic Lymphocytic Leukemia (CLL) and Non‐Hodgkin's Lymphoma and Exposure–Response in CLL | CPT: Pharmacometrics and Systems Pharmacology | 2014 | 71 |
| 37 | Quantitative Characterization of the Exposure-Response Relationship for Cancer Immunotherapy: A Case Study of Nivolumab in Patients With Advanced Melanoma | CPT: Pharmacometrics and Systems Pharmacology | 2017 | 71 |
| 38 | Effect of CYP3A4*22, CYP3A5*3, and CYP3A Combined Genotypes on Cyclosporine, Everolimus, and Tacrolimus Pharmacokinetics in Renal Transplantation | CPT: Pharmacometrics and Systems Pharmacology | 2014 | 69 |
| 39 | Establishing Good Practices for Exposure–Response Analysis of Clinical Endpoints in Drug Development | CPT: Pharmacometrics and Systems Pharmacology | 2015 | 67 |
| 40 | Dynamic Modeling of the Interaction Between Autophagy and Apoptosis in Mammalian Cells | CPT: Pharmacometrics and Systems Pharmacology | 2015 | 67 |
| 41 | Developing Exposure/Response Models for Anticancer Drug Treatment: Special Considerations | CPT: Pharmacometrics and Systems Pharmacology | 2015 | 66 |
| 42 | FDA Advisory Meeting Clinical Pharmacology Review Utilizes a Quantitative Systems Pharmacology (QSP) Model: A Watershed Moment? | CPT: Pharmacometrics and Systems Pharmacology | 2015 | 66 |
| 43 | Population Pharmacokinetic/Pharmacodynamic Modeling of Tumor Size Dynamics in Pembrolizumab-Treated Advanced Melanoma | CPT: Pharmacometrics and Systems Pharmacology | 2017 | 66 |
| 44 | Application of a Physiologically Based Pharmacokinetic Model to Predict OATP1B1‐Related Variability in Pharmacodynamics of Rosuvastatin | CPT: Pharmacometrics and Systems Pharmacology | 2014 | 64 |
| 45 | A Six‐Stage Workflow for Robust Application of Systems Pharmacology | CPT: Pharmacometrics and Systems Pharmacology | 2016 | 63 |
| 46 | NONMEM Tutorial Part II: Estimation Methods and Advanced Examples | CPT: Pharmacometrics and Systems Pharmacology | 2019 | 63 |
| 47 | CPT: Pharmacometrics and Systems Pharmacology | CPT: Pharmacometrics and Systems Pharmacology | 2012 | 62 |
| 48 | Predictive Performance of Physiologically Based Pharmacokinetic and Population Pharmacokinetic Modeling of Renally Cleared Drugs in Children | CPT: Pharmacometrics and Systems Pharmacology | 2016 | 62 |
| 49 | A model qualification method for mechanistic physiological QSP models to support model‐informed drug development | CPT: Pharmacometrics and Systems Pharmacology | 2016 | 62 |
| 50 | Development of a Multicompartment Permeability‐Limited Lung PBPK Model and Its Application in Predicting Pulmonary Pharmacokinetics of Antituberculosis Drugs | CPT: Pharmacometrics and Systems Pharmacology | 2015 | 61 |
